Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 1432597-26-6 Chemical Structure| 1432597-26-6
Chemical Structure| 1432597-26-6

LDN-212854

CAS No.: 1432597-26-6

LDN-212854 is an inhibitor of BMP and can inhibit ALK2 with IC50 of 1.3 nM. It is used to prevent heterotopic ossification.

Synonyms: BMP Inhibitor III

4.5 *For Research Use Only !

Cat. No.: A189348 Purity: 98%

Change View

Size Price

US Stock

Global Stock

In Stock
1mg łò˶ÊÊ Inquiry Inquiry
5mg łďî¶ÊÊ Inquiry Inquiry
10mg łÇÊ˶ÊÊ Inquiry Inquiry
25mg łÇ§Ë¶ÊÊ Inquiry Inquiry
50mg łËËͶÊÊ Inquiry Inquiry
100mg ł§óǶÊÊ Inquiry Inquiry
250mg łďË˶ÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1mg

    łò˶ÊÊ

  • 5mg

    łďî¶ÊÊ

  • 10mg

    łÇÊ˶ÊÊ

  • 25mg

    łÇ§Ë¶ÊÊ

  • 50mg

    łËËͶÊÊ

  • 100mg

    ł§óǶÊÊ

  • 250mg

    łďË˶ÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Alternative Products

Product Details of LDN-212854

CAS No. :1432597-26-6
Formula : C25H22N6
M.W : 406.48
SMILES Code : C12=C(C3=C4N=CC(C5=CC=C(N6CCNCC6)C=C5)=CN4N=C3)C=CC=C1N=CC=C2
Synonyms :
BMP Inhibitor III
MDL No. :MFCD28099808
InChI Key :BBDGBGOVJPEFBT-UHFFFAOYSA-N
Pubchem ID :60182388

Safety of LDN-212854

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301
Precautionary Statements:P301+P310
Class:6.1
UN#:2811
Packing Group:

Isoform Comparison

Biological Activity

Target
  • ALK1

    ALK1, IC50:2.4 nM

  • TGFβRI/ALK5

    ALK5, IC50:9276 nM

  • ALK2

    ALK2, IC50:1.3 nM

  • ALK3

    ALK3, IC50:85.8 nM

  • ALK4

    ALK4, IC50:2133 nM

In Vitro:

Cell Line
Concentration Treated Time Description Reference
Huh7 cells 1 μM 48 hours PMC8835914
Hep3B cells 5 ng/mL 48 hours BMP9 promotes cell cycle progression by reducing RNA m6A methylation levels PMC10816017
Huh7 cells 5 ng/mL 48 hours PMC10816017
MT cells 1 μM 48 hours Suppressed HIF-1α/VEGFA expression and VEGFA secretion PMC8835914
Human DIPG cell lines (SU DIPG IV, DIPG007, SF8628) 0.1 μM to 10 μM To evaluate the effect of LDN212854 on proliferation of human DIPG cell lines, results showed that ACVR1 mutant cell lines were more sensitive to LDN212854. PMC6399349
Mesenchymal cells 750 nM 12, 24, 48, 72, and 96 hr Evaluate the effect of LDN-212854 on mesenchymal cell proliferation, results show LDN-212854 significantly reduces cell proliferation PMC5542633
Primary rat OPCs 0.18 μM 3 days To evaluate the effect of LDN-212854 on OPC differentiation in the presence of fibrinogen, results showed that LDN-212854 restored mature oligodendrocyte differentiation and reduced GFAP+ astrocyte formation. PMC8418337
HSG cells 0.1, 1.0 or 10 nM 4 days To investigate the effect of LDN-212854 on BMP6-induced loss of cell membrane water permeability. Results showed that LDN-212854 inhibited BMP6-induced RVD loss in a dose-dependent manner. PMC7031521
HSG cells 10 or 60 nM 24 hours To investigate the effect of LDN-212854 on BMP6-induced loss of cell membrane water permeability. Results showed that LDN-212854 inhibited BMP6-induced RVD loss in a dose-dependent manner. PMC7031521
C2C12 cells 500 nM 3 days To test the inhibitory effect of LDN-212854 on BMP2-induced alkaline phosphatase (ALP) activity, results showed that LDN-212854 significantly suppressed ALP activity. PMC10998299
Human mesenchymal stromal cells (MSCs) 500 nM 28 days To test the effect of LDN-212854 on MSC chondrogenesis in vitro, results showed that LDN-212854 mildly inhibited chondrogenesis but had limited effects on hypertrophy markers. PMC10998299
Bone marrow mononuclear cells (BMMs) 1 μM 5 days LDN-212854 inhibits SMAD1/5/9 phosphorylation, thereby inhibiting osteoclastogenesis in caAcvr1 mutant cells. PMC6879329

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description Reference
Mouse Acvr1[R206H]FlEx/+ conditional knock-in mice Subcutaneous injection 3 mg/kg Twice daily for 4 weeks LDN-212854 effectively suppressed spontaneous joint/ligament HO and injury-triggered intramuscular HO in Acvr1R206H mice, demonstrating selective ACVR1 inhibition abrogates cell-autonomous effects of mutant receptors in tendon and muscle progenitors. PMC6407419
Mice Ntv-a;p53fl/fl mice Intraperitoneally 10 mg/kg (in vitro), 6 mg/kg (in vivo survival study) Twice daily for 5 consecutive days (in vitro); twice a day until euthanasia endpoints were met (in vivo survival study) To evaluate the effect of LDN212854 on tumor growth and survival, results showed that LDN212854 significantly prolonged survival. PMC6399349
Mice Burn/tenotomy model Intraperitoneal injection 6 mg/kg Daily for 6 weeks Evaluate the effect of LDN-212854 on trauma-induced heterotopic ossification, results show LDN-212854 significantly reduces heterotopic ossification volume PMC5542633
Mice Chronic MOG 35-55 EAE model and progressive EAE model in non-obese diabetic mice 14 days (MOG 35-55 EAE) and 30 days (non-obese diabetic EAE) To evaluate the therapeutic effects of LDN-212854, results showed that LDN-212854 significantly improved clinical scores, reduced fibrinogen deposition and demyelination, and decreased NG2 cell clustering and myelin damage. PMC8418337
Mice C57BL/6.NOD-Aec1Aec2 mouse model Intraperitoneal injection 2.5 mg/kg Once daily for 24 days To investigate the effect of LDN-212854 on the restoration of salivary gland function in C57BL/6.NOD-Aec1Aec2 mice. Results showed that LDN-212854 treatment significantly increased salivary flow rate and reduced phosphorylation of SMAD1/5/8 and expression of ID3. PMC7031521
NCG mice HCC xenograft model Intraperitoneal injection 6 mg/kg Twice daily for 10-14 days LDN-212854 significantly suppressed HCC tumor growth and induced global RNA m6A methylation PMC10816017
NOD/SCID mice HCC xenograft model Intraperitoneal injection 6 mg/kg Twice daily for 10-14 days Inhibited HCC tumor growth and angiogenesis PMC8835914

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.46mL

0.49mL

0.25mL

12.30mL

2.46mL

1.23mL

24.60mL

4.92mL

2.46mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories